Genetic deletion of PD-1 enhances anti-tumor T cell therapy

Researchers from University College London (UCL) Cancer Institute and Cellectis S.A. (Euronext: ALCLS; NASDAQ: CLLS)

Read the full 154 word article

User Sign In